Alexion Seizes On New Soliris Indication, Business Development For Growth

Alexion will target Soliris to about 3,000-8,000 US patients with ultra-rare generalized myasthenia gravis (gMG) following FDA approval. Meanwhile, the company has hired a new head of business development.

Alexion Pharmaceuticals Inc. is targeting a new patient population with its blockbuster complement C5 inhibitor Soliris (eculizumab), patients with the ultra-rare neuromuscular condition generalized myasthenia gravis (gMG).

During the company's third quarter sales and earnings call Oct. 26, Chief Commercial Officer Brian Goff outlined some initial plans for expanding Soliris to the new patients. There are about 60,000 to 80,000 patients in the US with gMG, he said, but FDA cleared the drug for a small subset of those patients. FDA approved Soliris Oct

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

08 May 2025

• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.